Gao Zhi-Hui, Bai Dou-Sheng, Jiang Guo-Qing, Jin Sheng-Jie
Zhi-Hui Gao, Dou-Sheng Bai, Guo-Qing Jiang, Sheng-Jie Jin, Hepato-bilio-pancreatic Surgery Department, Subei People's Hospital, Yangzhou University, Yangzhou 225001, Jiangsu Province, China.
World J Hepatol. 2015 Jan 27;7(1):40-3. doi: 10.4254/wjh.v7.i1.40.
Hepatocellular carcinoma (HCC) is one of the few cancers whose incidence has been continually increasing over recent years. Resection of HCC offers the only hope for cure. However, recurrences are common in patients who have undergone resection. In our opinion, the effectiveness with which transarterial chemoembolization (TACE) as a neoadjuvant therapy for resectable HCC prevents recurrence and prolongs survival has not been conclusively demonstrated. All published meta-analyses have consistently failed to demonstrate that preoperative TACE improves the prognosis of resectable HCC. We believe that these published articles have several limitations and have our own views about the results of meta-analyses. It is very important that the scientific community shed more light on the pathogenesis of HCC and relate this to choice of therapy. This review mainly concerns our understanding of preoperative TACE for resectable HCC and briefly addresses desirable directions for future studies.
肝细胞癌（HCC）是近年来少数几种发病率持续上升的癌症之一。肝癌切除术是治愈的唯一希望。然而，接受过切除术的患者复发很常见。我们认为，经动脉化疗栓塞术（TACE）作为可切除肝癌的新辅助治疗方法预防复发和延长生存期的有效性尚未得到确凿证实。所有已发表的荟萃分析均未能证明术前TACE能改善可切除肝癌的预后。我们认为这些已发表的文章存在若干局限性，并且对荟萃分析的结果有我们自己的看法。科学界更深入地了解HCC的发病机制并将其与治疗选择联系起来非常重要。本综述主要涉及我们对可切除肝癌术前TACE的理解，并简要阐述未来研究的理想方向。
